Neurosense Therapeutics Ltd.

Biotechnology • Healthcare • Herzliya, Israel • NRSNW (NCM)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

972 9 799 6183 Building B, Israel

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Nasdaq • Dec 22

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PR Newswire

PR Newswire • Sep 4

Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan

Stock Titan • Dec 22

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks

TipRanks • Dec 4

NeuroSense Provides Business Update and Progress for the First Half of 2025 - Yahoo Finance

Yahoo Finance • Aug 1

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has NeuroSense Therapeutics Ltd. had layoffs?

No layoff events have been recorded for NeuroSense Therapeutics Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does NeuroSense Therapeutics Ltd. have?

NeuroSense Therapeutics Ltd. has approximately 17 employees.

What industry is NeuroSense Therapeutics Ltd. in?

NeuroSense Therapeutics Ltd. operates in the Biotechnology industry, within the Healthcare sector.

Is NeuroSense Therapeutics Ltd. a publicly traded company?

Yes, NeuroSense Therapeutics Ltd. is publicly traded under the ticker symbol NRSNW on the NCM.

Where is NeuroSense Therapeutics Ltd. headquartered?

NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel at Building B, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.